Overexpression of PSAT1 is Correlated with Poor Prognosis and Immune Infiltration in Non-Small Cell Lung Cancer.

Purpose: Current evidence suggests that phosphoserine aminotransferase 1 () is overexpressed in various tumors. Herein, we investigate the significance of in non-small cell lung cancer (NSCLC) and its correlation with immune infiltration.

Methods: The expression profile of in NSCLC patients and related clinical information was obtained from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA-NSCLC) databases. and experimental validation were conducted to assess the role of in NSCLC. Gene set enrichment analysis (GSEA) was performed to investigate the disparities in biological functions between groups with high and low expression. Additionally, the biological characteristics and immune cell infiltration were compared between these two groups. We also assessed whether expression could predict the sensitivity of NSCLC patients to immunotherapy using the immunophenotype score (IPS) and an anti-PD-L1 immunotherapy cohort (IMvig-or210). Furthermore, the difference in drug sensitivity between -high and -low expression cell lines was investigated.

Results: Analysis of transcriptional expression profiles using TCGA data revealed overexpression of in NSCLC tissues correlated with poor overall survival (OS). GSEA results showed enrichment of DNA recombination and repair, nucleotide biosynthesis, and the P53 signaling pathway in the -high group. Experimental validation demonstrated that the knockdown of suppressed cell proliferation, migration, and invasion of NSCLC. Immune cell infiltration analysis revealed an immune-activated tumor microenvironment in the -low group. It was also observed that -low cell lines were more likely to benefit from immunotherapy and several chemotherapy drugs.

Conclusions: has enormous potential for applications in the prediction of NSCLC patient outcomes and provides the foothold for more precise individualized treatment of this patient population.